

PLURISTEM LIFE SYSTEMS INC  
Form 8-K  
November 26, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 26, 2007**

**PLURISTEM THERAPEUTICS INC.**  
(Exact name of registrant as specified in its charter)

**NEVADA**  
(State or other jurisdiction  
of incorporation)

**001-31392**  
(Commission  
File Number)

**98-0351734**  
(IRS Employer  
Identification No.)

**MATAM Advanced Technology Park, Building No. 20, Haifa, Israel**  
(Address of principal executive offices)

**31905**  
(Zip Code)

**+972-74-710-7171**  
(Registrant's telephone number, including area code)

**PLURISTEM LIFE SYSTEMS, INC.**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On November 26, 2007, the registrant issued a press release announcing the effectiveness of its reverse stock split and change of name to Pluristem Therapeutics Inc., as well as its new trading symbol. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release issued by the registrant on November 26, 2007

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PLURISTEM THERAPEUTICS INC.  
(registrant)

By: /s/ Zami Aberman

Date: November 26, 2007

Name: Zami Aberman  
Title: Chief Executive Officer

---